Clinical Trials Browser

Phase 2 × Hematologic Diseases × Bortezomib × Clear all

NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Phase 2 Completed

57 enrolled 22 charts

Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

51 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell